Abstract
No public abstract is available from the verified source records.
Panagiotis-Anastasios Tsioufis, Dimitrios Tsiachris, Nikos Argyriou, Michail Botis, Ioannis Doundoulakis, Athanasios Kordalis, Christos-Konstantinos Antoniou, Giorgos Matthaiopoulos, Ioannis Zamanis, Constantinos Mihas, Sotirios Xydonas, Sotirios Patsilinakos, Nikolaos Kafkas, Konstantinos Gatzoulis, Konstantinos Tsioufis
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
10.1093/eurheartj/ehae176 · 2024
Mortality and morbidity in patients receiving encainide, flecainide, or placebo
1991
Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis
10.1161/circep.121.010321 · 2021
Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED)
10.3390/jcm12123961 · 2023
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
10.1093/eurheartj/ehz425 · 2020
Unresolved referenced work
2020
Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis
10.1007/s10557-020-07127-1 · 2021
10.1002/9781118458167
10.1002/9781118458167
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1161/01.cir.90.6.2843 · 1994
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial
10.1016/0002-9149(91)90308-8 · 1991
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I
10.1136/hrt.74.6.631 · 1995
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)
10.1016/s0002-9149(02)02867-9 · 2002
Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort
10.1016/j.hrthm.2026.02.042 · 2026
Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST
10.1016/j.hrthm.2025.08.034 · 2026
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease
10.1016/j.jacep.2022.12.021 · 2023
Expanding the indications for flecainide: Good idea or CAST reprise?
10.1016/j.hrthm.2025.09.030 · 2026
Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: A systematic review
10.1016/j.hrthm.2026.02.010 · 2026
2026 HRS/PACES scientific statement on the use of antiarrhythmic drugs in understudied clinical scenarios
10.1016/j.hrthm.2026.07.012 · 2026
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
10.1016/0735-1097(95)00595-1 · 1996
Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis
10.1016/s0735-1097(02)02705-5 · 2003
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
10.1016/s0002-9149(00)01128-0 · 2000
Impact of emergency department management of atrial fibrillation on hospital charges
10.5811/westjem.2012.1.6893 · 2013
No additional external references are available.